Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMNJAVV)

Drug Name
Zinpentraxin alfa Drug Info
Indication
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMNJAVV

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serum amyloid P-component (APCS) TTB7VAT SAMP_HUMAN Replacement [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Serum amyloid P-component (APCS) DTT APCS 12.393 5.113 5.459 5.182
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Idiopathic pulmonary fibrosis
ICD Disease Classification CB03.4
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serum amyloid P-component (APCS) DTT APCS 3.02E-01 -0.06 -0.21
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04552899) A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis. U.S.National Institutes of Health.
2 Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica. 2023 Oct 1;108(10):2730-2742.